These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27792159)

  • 1. Pseudomonas aeruginosa Type III Secretory Toxin ExoU and Its Predicted Homologs.
    Sawa T; Hamaoka S; Kinoshita M; Kainuma A; Naito Y; Akiyama K; Kato H
    Toxins (Basel); 2016 Oct; 8(11):. PubMed ID: 27792159
    [No Abstract]   [Full Text] [Related]  

  • 2. A novel phosphatidylinositol 4,5-bisphosphate binding domain mediates plasma membrane localization of ExoU and other patatin-like phospholipases.
    Tyson GH; Halavaty AS; Kim H; Geissler B; Agard M; Satchell KJ; Cho W; Anderson WF; Hauser AR
    J Biol Chem; 2015 Jan; 290(5):2919-37. PubMed ID: 25505182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudomonas aeruginosa causes acute lung injury via the catalytic activity of the patatin-like phospholipase domain of ExoU.
    Pankhaniya RR; Tamura M; Allmond LR; Moriyama K; Ajayi T; Wiener-Kronish JP; Sawa T
    Crit Care Med; 2004 Nov; 32(11):2293-9. PubMed ID: 15640644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a review.
    Sawa T; Shimizu M; Moriyama K; Wiener-Kronish JP
    Crit Care; 2014 Dec; 18(6):668. PubMed ID: 25672496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysophospholipase A activity of Pseudomonas aeruginosa type III secretory toxin ExoU.
    Tamura M; Ajayi T; Allmond LR; Moriyama K; Wiener-Kronish JP; Sawa T
    Biochem Biophys Res Commun; 2004 Apr; 316(2):323-31. PubMed ID: 15020221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ExoU is a potent intracellular phospholipase.
    Sato H; Frank DW
    Mol Microbiol; 2004 Sep; 53(5):1279-90. PubMed ID: 15387809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of superoxide dismutase as a cofactor for the pseudomonas type III toxin, ExoU.
    Sato H; Feix JB; Frank DW
    Biochemistry; 2006 Aug; 45(34):10368-75. PubMed ID: 16922513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU.
    Sato H; Frank DW; Hillard CJ; Feix JB; Pankhaniya RR; Moriyama K; Finck-Barbançon V; Buchaklian A; Lei M; Long RM; Wiener-Kronish J; Sawa T
    EMBO J; 2003 Jun; 22(12):2959-69. PubMed ID: 12805211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: from bacterial pathogenesis to host response.
    Sawa T
    J Intensive Care; 2014; 2(1):10. PubMed ID: 25520826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation of the phospholipase catalytic domain of the Pseudomonas aeruginosa cytotoxin ExoU abolishes colonization promoting activity and reduces corneal disease severity.
    Tam C; Lewis SE; Li WY; Lee E; Evans DJ; Fleiszig SM
    Exp Eye Res; 2007 Dec; 85(6):799-805. PubMed ID: 17905228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis of cytotoxicity mediated by the type III secretion toxin ExoU from Pseudomonas aeruginosa.
    Gendrin C; Contreras-Martel C; Bouillot S; Elsen S; Lemaire D; Skoufias DA; Huber P; Attree I; Dessen A
    PLoS Pathog; 2012; 8(4):e1002637. PubMed ID: 22496657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of the effector ExoU from
    Springer TI; Reid TE; Gies SL; Feix JB
    J Biol Chem; 2019 Dec; 294(50):19012-19021. PubMed ID: 31662432
    [No Abstract]   [Full Text] [Related]  

  • 13. Eukaryotic localization, activation and ubiquitinylation of a bacterial type III secreted toxin.
    Stirling FR; Cuzick A; Kelly SM; Oxley D; Evans TJ
    Cell Microbiol; 2006 Aug; 8(8):1294-309. PubMed ID: 16882033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of ExoU phospholipase activity requires specific C-terminal regions.
    Schmalzer KM; Benson MA; Frank DW
    J Bacteriol; 2010 Apr; 192(7):1801-12. PubMed ID: 20097856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Difference of Type 3 secretion system (T3SS) effector gene genotypes (exoU and exoS) and its implication to antibiotics resistances in isolates of Pseudomonas aeruginosa from chronic otitis media.
    Park MH; Kim SY; Roh EY; Lee HS
    Auris Nasus Larynx; 2017 Jun; 44(3):258-265. PubMed ID: 27461174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and characterization of SpcU, a chaperone required for efficient secretion of the ExoU cytotoxin.
    Finck-Barbançon V; Yahr TL; Frank DW
    J Bacteriol; 1998 Dec; 180(23):6224-31. PubMed ID: 9829931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Psychrotrophic Pseudomonas lundensis, a Non-
    Ravi K; Falkowski NR; Scales BS; Akulava VD; Valentovich LN; Huffnagle GB
    mBio; 2022 Feb; 13(1):e0386921. PubMed ID: 35189702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary description of biocidal (syringomycin) activity in fluorescent plant pathogenic Pseudomonas species.
    Hu FP; Young JM; Fletcher MJ
    J Appl Microbiol; 1998 Aug; 85(2):365-71. PubMed ID: 9750309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of phospholipase activity of the Pseudomonas aeruginosa type III cytotoxin, ExoU.
    Sato H; Feix JB; Hillard CJ; Frank DW
    J Bacteriol; 2005 Feb; 187(3):1192-5. PubMed ID: 15659695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional regions of the Pseudomonas aeruginosa cytotoxin ExoU.
    Rabin SD; Hauser AR
    Infect Immun; 2005 Jan; 73(1):573-82. PubMed ID: 15618197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.